DISCLAIMER
This is in no way, shape or form, fluid and function, an analytical, qualitative or intelligent compte rendu. There is absolutely no financial advice here because the only financial advice I can give is to research, research, and research. The purpose of this analysis is to serve as an example of an investigation into a company's background,...
Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care.
An independent Data and Safety Monitoring Board concluded that "a...
Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy
EDSA has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause...
Hello everybody and happy new year! ❤
Major retest of breaking 6-7 years of channel Resistance. The retest after a very strong impulsive move out of the channel is forming a falling wedge with very tight price consolidation. Another plus about this stock is that it has a very low float. I like accumulation here, maybe one more chance at 3.56
I'm extremely...
Yesterday they knocked EDSA out of the ball park to $19! today it is close to where it started from two days prior. Great opportunity for a possible final boss round (Phase 3). Very good phase 3 results often 10x a company's stock price. EDSA is currently phase 1 and phase 2.
COVID news had EDSA gap up to $19 and as long as COVID is front and center stage,...
Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study
clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients.
The company recently received expedited approval to begin the Phase 2/3 study in Canada and is seeking government grants to accelerate site selection and initiate patient enrollment
The safety...
During the summer time I was beginning to notice that the price would spike after somebody visited one of my old articles that had been spammed on ihub or yahoo.
I said I had a source back October lol, and I'll just tell you the truth: it was my website. I had been receiving some unusual traffic from one of my earlier articles that I had written about this...
**Let us say I have a source**
THIS IS FOR EXPERIENCED SMALL CAP TRADERS ONLY
They had 7,504,468 shares outstanding going by their S-3 dated August 29, 2019. The S-3 has been approved and it is for $50,000,000.
$6,363,096 in cash as of June.30th, and they reported a $1,822,837 loss over the first 6 months of this year
Ownership is highly concentrated
...
Hey there Trader's! This stock exploded today with huge volatility, and made an impressive 45% gain today . I'll be watching this tomorrow for possible continuation, looking for break and re-test of the important level of 7.90 , I've set my alert! I didn't see any see any news that was released today. If your holding stock, definitely watch 5.71 as a break...
